Alithea Genomics secures CHF 2.8 million in Seed financing extension led by Novalis Biotech
14.03.2024
The funding will support the commercialization and manufacturing of Alithea's innovative RNA sequencing products, drive new technology development, and establish a subsidiary in the US.
 Alithea Genomics' team
|
 |
Alithea commercializes multiplexed library preparation solutions for RNA sequencing, most notably BRB-seq and DRUG-seq. These technologies prepare hundreds of RNA samples for sequencing in a single tube and, in the case of DRUG-seq, without needing RNA isolation. Traditional preparation of samples for RNA sequencing is expensive and time-consuming, due to the large amounts of reagents and manual operations that are typically required. Alithea’s BRB-seq technology drastically decreases the cost and time associated with RNA sequencing preparation.
Since the initial seed financing, Alithea Genomics has made significant progress in growing its product portfolio, especially with the addition of DRUG-seq, which is now used by several big pharma companies to improve drug development processes.
Alithea has moved to its new HQ in Lausanne, Switzerland, with dedicated labs and equipment. In addition, the Biotech startup has expanded its overall production and service capacity, which now allows for tens of thousands of RNA samples to be processed quickly and with high quality.
Alithea participated in Venture Leaders Biotech and won the last stage of Venture Kick in 2021. "Venture Leaders and Venture Kick have been instrumental in the first phases of Alithea's growth. They significantly facilitated our transition from a small academic spin-off to a fast-growing life science company. This was made possible not only by the access to early funds but also importantly, to a network of experts and partners that proved essential over the years," said CEO Riccardo Dainese.
Alithea's Co-founders: CTO Daniel Alpern, Scientific Advisor Bart Deplancke, and CEO Riccardo Dainese
Since the initial seed financing, Alithea Genomics has made significant progress in growing its product portfolio, especially with the addition of DRUG-seq, which is now used by several big pharma companies to improve drug development processes.
Alithea has moved to its new HQ in Lausanne, Switzerland, with dedicated labs and equipment. In addition, the Biotech startup has expanded its overall production and service capacity, which now allows for tens of thousands of RNA samples to be processed quickly and with high quality.
Alithea participated in Venture Leaders Biotech and won the last stage of Venture Kick in 2021. "Venture Leaders and Venture Kick have been instrumental in the first phases of Alithea's growth. They significantly facilitated our transition from a small academic spin-off to a fast-growing life science company. This was made possible not only by the access to early funds but also importantly, to a network of experts and partners that proved essential over the years," said CEO Riccardo Dainese.
Alithea's Co-founders: CTO Daniel Alpern, Scientific Advisor Bart Deplancke, and CEO Riccardo Dainese